Although VDZ is successfully used for treatment of IBD naïve patients or for patients who have failed TNF-α antagonists [5], a significant proportion of patients does not respond at induction or loses response over time, and might develop significant side effects [6–8]. Here, TNF is linked to inflammatory bowel disease.